KLOW peptide dosage: what the component studies used and what the blend record is silent on

In plain English

KLOW peptide comes as a lyophilized powder — a freeze-dried solid — in a research vial. The most widely referenced composition is 80 mg total: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. You reconstitute it by adding bacteriostatic water (water that contains a small amount of benzyl alcohol to prevent bacterial growth) to the vial. What happens after that — how often, how much, by which route — is where the component-level research stops and the combination data gap begins. No controlled human study has established a dose, a frequency, or a route for the four-peptide KLOW blend. The page below documents what the single-component studies measured and how they handled those compounds in the lab. It does not recommend a human dose because no such recommendation is supported by blend-level evidence.

KLOW peptide dosage: the canonical composition

The canonical research vial composition is 80 mg total, co-formulated as:

• GHK-Cu: 50 mg (62.5% by mass)
• BPC-157: 10 mg
• TB-500: 10 mg
• KPV: 10 mg

This split reflects GHK-Cu's role as the mass-dominant component and the skin-matrix lead. Independent compounders vary the ratios; 50/10/10/10 is the most widely referenced. No pharmacopeial standard exists for this mixture.

Reconstitution: the lyophilized powder is typically reconstituted with bacteriostatic water for laboratory handling. The reconstituted solution is stored refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with the three other peptides that has not been formally characterized for this mixture.

No validated human dosing exists for the four-peptide blend.

KLOW dosage

Component-level research doses from the single-component studies, for context:

KPV: In DSS- and TNBS-colitis mouse models, oral KPV was administered at 100 micromolar in drinking water ^[3]. In vitro, nanomolar KPV (10 nM) was active against NF-kappaB and MAPK signaling ^[3]. These are mouse and cell-culture figures; they are not a basis for a human dose recommendation.

GHK-Cu: In vitro gene-expression studies used 1 to 10 nM ^[5]. Clinical topical trials have used formulated GHK-Cu creams at undisclosed concentrations. The penetration study used a glycyl-L-histidyl-L-lysine cuprate diacetate topical preparation ^[8]. No systemic human dose has been established in clinical trials for GHK-Cu.

BPC-157: In rat Achilles tendon studies, BPC-157 was administered intraperitoneally at 10 μg, 10 ng or 10 pg per rat once daily ^[2]. In the 2025 human IV safety pilot, the dose was 10 mg on day 1 and 20 mg on day 2, administered as a 1-hour infusion in 250 mL saline ^[6]. This is a two-person safety signal only, not an established dose.

TB-500 / thymosin beta-4: In the rat wound model, topical or intraperitoneal thymosin beta-4 was studied; as little as 10 pg stimulated keratinocyte migration ^[1]. These figures apply to full-length native thymosin beta-4, not the TB-500 fragment. No human dose is established for TB-500.

KLOW peptide dosage and frequency

The published component literature does not converge on a single frequency for any of the four compounds in a human context, and no study has addressed KLOW blend dosing frequency at all. Frequency data from the component literature are rodent protocols and are not transferable.

An additional variable is the pharmacokinetic mismatch: the tripeptides KPV and GHK-Cu clear substantially faster than BPC-157, and TB-500's clearance differs from native thymosin beta-4. A single co-formulated administration therefore does not deliver all four components at matched exposures. Whether higher-frequency administration would compensate — and how — is an open research question with no published answer.

Routes studied in the component literature

Different components have been studied by different routes, creating a practical complexity for a co-formulated blend:

KPV: oral/enteral (drinking water in mice); cell culture medium in vitro. PepT1-mediated uptake suggests the gut epithelium is the primary target tissue for oral administration ^[3].

GHK-Cu: topical application is the most extensively documented route in humans (skin penetration, cosmetic trials, the hair study). Systemic routes (IV, SC) have not been formally studied in humans for GHK-Cu ^[4][8].

BPC-157: intraperitoneal in rodent studies; intravenous in the 2025 human safety pilot ^[2][6]; oral and intra-articular routes have also been explored in the rodent literature.

TB-500 / thymosin beta-4: subcutaneous and intraperitoneal in the wound and cardiac models; topical in the wound study ^[1].

The KLOW blend, as a research vial, is typically described in community contexts as subcutaneous. The appropriateness of any route for laboratory handling is a question for the researcher and the relevant research protocol, not a claim this editorial site makes.

Stability and handling notes

The lyophilized KLOW blend is typically stored frozen or refrigerated before reconstitution. Reconstituted solution is refrigerated and used within the period specified for the individual components. Copper(II) ions in GHK-Cu can catalyze oxidation reactions; co-dissolving a copper-chelated peptide with three other peptides in one solution is a theoretical stability consideration that has not been formally characterized for this mixture. This is relevant to anyone handling the blend in a laboratory context.